PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10390207-2 1999 The metallo-beta-lactamase determinant was isolated from a genomic library of VR-143/97, constructed in an Escherichia coli plasmid vector, by screening for clones with reduced susceptibility to imipenem. Imipenem 195-203 beta-lactamase Escherichia coli 12-26 10223937-9 1999 However, measurement of beta-lactamase activities (including measurements under conditions where TEM-1 beta-lactamase was inhibited) indicated that the imipenem-intermediate isolate expressed six- to eightfold less beta-lactamase than did the other isolates. Imipenem 152-160 beta-lactamase Escherichia coli 103-117 34657270-4 2021 MBLs and AmpC production were phenotypically detected by imipenem-ethylenediaminetetracetate and cefoxitin/boronic acid assays, respectively. Imipenem 57-65 beta-lactamase Escherichia coli 9-13 2847278-0 1988 Molecular cloning and expression of the imipenem-hydrolyzing beta-lactamase gene from Pseudomonas maltophilia in Escherichia coli. Imipenem 40-48 beta-lactamase Escherichia coli 61-75 3911882-3 1985 High production of cloned E. coli chromosomal beta-lactamase, however, provided resistance to cefamandole, cefoxitin, cefotaxime, ceftazidime, and aztreonam but not to BMY-28142 or imipenem. Imipenem 181-189 beta-lactamase Escherichia coli 46-60 32364269-7 2021 All AmpC and/or ESBL-phenotype E. coli were sensitive to colistin, ertapenem, imipenem, meropenem, temocillin and tigecycline, applying epidemiological cut-off values. Imipenem 78-86 beta-lactamase Escherichia coli 4-8 32152073-1 2020 Imipenem/relebactam (I/R) is a recently developed carbapenem/beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in Escherichia coli, including sequence type 131 (ST131) and its fluoroquinolone-resistant H30R subclone, the leading cause of extra-intestinal E. coli infections globally. Imipenem 0-8 beta-lactamase Escherichia coli 61-75 29796032-13 2018 Imipenem and meropenem showed potent antibacterial activities against all MDR beta-lactamase-producers except for carbapenemase producers. Imipenem 0-8 beta-lactamase Escherichia coli 78-92